Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.

Randomised, Double-blind Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS ® Inhlaer 50/100mcg Twice Daily vs. FLIXOTIDE® Inhaler 200mcg Twice Daily.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00169546

Enrollment

Registered

2005-09-15

Start date

2003-01-31

Completion date

2005-12-31

Last updated

2016-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma, inhaled corticosteroids

Brief summary

Comparison of two asthma treatments by lung function measures.

Interventions

DRUGSalmeterol/fluticasone propionate

DRUGFluticasone propionate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

4 Years to 11 Years

Healthy volunteers

Inclusion criteria

* Currently receiving 200-800mcg/day beclomethasone dipropionate. * sRAW value of 1.3 kPa's.

Exclusion criteria

* 3 or more courses of oral steroids in last 12 months.

Design outcomes

Primary

Measure	Time frame
sRAW (k.Pa.s) measured before the study medication dose at the end of treatment (week 6)	—

Secondary

Measure	Time frame
sRAW measured pre-dose at Week 3. sRAW measured 48 hours after last study medication dose. % symptom-free days over Weeks 1-6. % symptom-free nights over Weeks 1-6. Type and frequency of adverse events.	—

Countries

New Zealand, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026